Patents by Inventor Lars Björck
Lars Björck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190079104Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.Type: ApplicationFiled: September 21, 2018Publication date: March 14, 2019Inventors: Lars BJÖRCK, Bertil CHRISTENSSON, Heiko HERWALD, Adam LINDER, Per AKESSON
-
Patent number: 10126312Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.Type: GrantFiled: May 12, 2016Date of Patent: November 13, 2018Assignee: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Patent number: 9784741Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.Type: GrantFiled: December 2, 2013Date of Patent: October 10, 2017Assignee: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Patent number: 9759720Abstract: It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis.Type: GrantFiled: September 23, 2011Date of Patent: September 12, 2017Assignee: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Publication number: 20160252529Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.Type: ApplicationFiled: May 12, 2016Publication date: September 1, 2016Inventors: Lars BJÖRCK, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Patent number: 8889128Abstract: The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.Type: GrantFiled: December 12, 2007Date of Patent: November 18, 2014Assignee: Hansa Medical ABInventors: Lars Björck, Mattias Collin, Arne Olsén, Rikard Holmdahl, Kutty Selva Nandakumar, Oonagh Shannon
-
Publication number: 20140187503Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.Type: ApplicationFiled: December 2, 2013Publication date: July 3, 2014Applicant: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Publication number: 20140080754Abstract: It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis.Type: ApplicationFiled: September 23, 2011Publication date: March 20, 2014Applicant: HANSA MEDICAL ABInventors: Lars Björck, Bertil Christensson, Adam Linder, Heiko Herwald, Per Åkesson
-
Publication number: 20140080925Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.Type: ApplicationFiled: February 7, 2012Publication date: March 20, 2014Applicant: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Patent number: 8518648Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.Type: GrantFiled: June 12, 2008Date of Patent: August 27, 2013Assignee: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Patent number: 8133483Abstract: The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.Type: GrantFiled: June 8, 2006Date of Patent: March 13, 2012Assignee: Hansa Medical ABInventors: Lars Björck, Rikard Holmdahl, Kutty Selva Nandakumar
-
Publication number: 20100305185Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.Type: ApplicationFiled: June 12, 2008Publication date: December 2, 2010Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Publication number: 20100303781Abstract: The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.Type: ApplicationFiled: June 8, 2006Publication date: December 2, 2010Inventors: Lars Björck, Rikard Holmdahl, Kutty Selva Nandakumar
-
Patent number: 7666582Abstract: A polypeptide isolated from S. pyogenes is described, having IgG cysteine protease activity. The protease is designated IdeS, Immunoglobulin G-degrading enzyme of S. pyogenes. A polypeptide comprises SEQ ID NO: 1 and variants and fragments thereof having IgG cysteine protease activity or the ability to generate an immune response against S. pyogenes in an individual. Polynucleotides encoding these polypeptides and the polypeptides may be used in generating an immune response in an individual. IdeS protease inhibitors may be used in the treatment of S. pyogenes infection.Type: GrantFiled: December 17, 2002Date of Patent: February 23, 2010Assignee: Hansa Medical Research ABInventors: Ulrich Von Pawel-Rammingen, Bjorn Johansson, Lars Björck
-
Publication number: 20060241031Abstract: An assay method for an anti-bacterial agent comprising: (a) providing as a first component protein SIC; (b) providing as a second component an antibacterial peptide; (c) contacting the first component with a test substance in the presence of the second component; and (d) determining the interaction or activity of the first component with the second component to determine thereby whether a test substance is an effective anti-bacterial agent.Type: ApplicationFiled: February 19, 2004Publication date: October 26, 2006Inventors: Per Akesson, Lars Björck, Anders Sjöholm
-
Patent number: 6843999Abstract: A polypeptide suitable for use in vaccination against Streptococcal infections comprises: a) the amino acid sequence of SEQ ID No 1; b) a variant of (a) which is capable of binding an anti-MtsA antibody; or (c) a fragment of (a) or (b) of at least 6 amino acids in length which is capable of binding an anti-MtsA antibody. A vaccine composition comprises: a) the amino acid sequence of SEQ ID No 1; b) a variant of (a) which is capable of generating an immune response to a Streptococcal; or (c) a fragment of (a) or (b) of at least 6 amino acids in length which is capable of generating an immune response against a Streptococcus.Type: GrantFiled: December 30, 1999Date of Patent: January 18, 2005Assignee: Actinova LimitedInventors: Lars Björck, Robert Janulczyk
-
Patent number: 6822075Abstract: The invention relates to sequences of protein L which bind to light chains of immunoglobulins. The invention also relates to hybrid proteins thereof which are able to bind to both light and heavy chains of immunoglobulin G, in particular protein LG. The invention also relates to DNA-sequences which code for the proteins, vectors which include such DNA-sequences, host cells which have been transformed with the vectors, methods for producing the proteins, reagent appliances for separation and identification of immunoglobulins, compositions and pharmaceutical compositions and pharmaceutical compositions which contain the proteins.Type: GrantFiled: October 26, 1994Date of Patent: November 23, 2004Assignee: Affitech ASInventors: Lars Björck, Ulf Sjöbring
-
Patent number: 6576741Abstract: A protein from Streptococcus pyogenes, serotype M1 has been characterized. This protein, called protein SIC, plays a role in S. pyogenes pathogenicity and virulence. It inhibits hemolysis by interacting with the plasma proteins clusterin, and members of the cystatin protein super family such as hisitidine rich glycoprotein (HRG). The protein comprises at least one of the following partial amino acid sequences: (a) glu thr tyr thr ser arg asn phe; (b) asp trp ser gly asp asp trp pro glu asp asp trp; (c) arg ser gly val gly leu ser gln tyr gly trp ser; (d) trp ser ser asp lys lys asp glu thr glu asp lyr thr; (e) gly thr gly tyr glu lys arg asp asp trp gly gly pro gly; (f) lys arg asp asp trp arg gly pro gly his ile pro lys pro. The protein and antibodies specific for the protein can be used in analytical procedures for determining the present of virulent Streptococcus pyrogens in a sample. The protein can also be used in vaccine compositions.Type: GrantFiled: September 8, 1998Date of Patent: June 10, 2003Assignee: Hansa Medical ABInventors: Per Åkesson, Lars Björck, Anders Sjoholm
-
Patent number: 6242210Abstract: An assay for compounds useful in the treatment of a bacterial induced coagulation disorder has the following steps: a) incubating a plasma sample with a strain of bacteria; b) adding a compound to be assayed to the plasma sample before, during or after step (a); c) conducting an activated partial thromboplastin time test; d) determining the clotting time.Type: GrantFiled: February 26, 1999Date of Patent: June 5, 2001Assignee: Actinova LimitedInventors: Lars Björck, Ulf Sjörbring, Abdelhakim Ben Nasr, Arne Olsén, Heiko Herwald, Werner Müller-Esterl, Eva Mattsson
-
Patent number: 6221845Abstract: Kinin antagonists, especially bradykinin antagonists, can be used for treating bacterial infections, in particular infections caused by bacteria belonging to the genera Streptococcus, Escherichia, Salmonella, Staphylococcus, Klebsiella, Moracella, Haemophilus and Yersinia.Type: GrantFiled: June 25, 1999Date of Patent: April 24, 2001Assignee: Actinova LimitedInventors: Lars Björck, Ulf Sjöbring, Abdelhakim Ben Nasr, Arne Olsén, Heiko Herwald, Werner Müller-Esterl